Primary malignant T cell lymphomas of the skin form a heterogenous group. Relevant classifications were recently made to separate different entities by various criteria. This is of great importance, because one should only rely on those therapeutical trials in which patients were included according such classifications. In this paper, we will mainly focus on therapeutic modalities for mycosis fungoides, which is the most frequent cutaneous T cell lymphoma and which may serve as a model disease. In principle, local (e.g., psoralens and ultraviolet A, PUVA) and systemic therapies (e.g., interferon-alpha 2a) can be applied. Very recently, we were able to demonstrate that even in initial stages of mycosis fungoides, the T cell clone is not restricted to the skin, but rather is present in low amounts in the peripheral blood. Therefore, systemic therapeutic modalities alone or in combination with local strategies (interferon-alpha 2a and acitretin/PUVA and interferon-alpha 2a) should be more effective, which will be proven by currently running clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-3-642-78771-3_31 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Over the last decade, Hippo signaling has emerged as a major tumor-suppressing pathway. Its dysregulation is associated with abnormal expression of and -family genes. Recent works have highlighted the role of YAP1/TEAD activity in several cancers and its potential therapeutic implications.
View Article and Find Full Text PDFHyperlipidaemia treatment and gut microbiology.
Front Microbiol
January 2025
Shaanxi Provincial Nuclear Industry 215 Hospital, Xianyang, Shaanxi, China.
Numerous studies have shown that hyperlipidaemia is closely related to the gut microbiota, and the study of microbiota in the treatment of hyperlipidaemia is undoubtedly a new target for the treatment and prevention of hyperlipidaemia. The efficacy of regulating the gut microecology and changing the structure of gut flora has been demonstrated by both western and traditional medication, biological therapy, and dietary exercise, so it is particularly important to study the relationship between gut microbiota and the treatment of hyperlipidaemia. In this review, we summarize the mechanism and relationship between the pathogenesis of hyperlipidaemia and gut microbiota, and the mechanism of hyperlipidaemia treatment by influencing the gut microbiota in various treatment modalities, which provides diversified therapeutic ideas and scientific basis for clinical treatment.
View Article and Find Full Text PDFCoronary Microvascular Dysfunction: Insights on Prognosis and Future Perspectives.
Rev Cardiovasc Med
January 2025
Division of Cardiology, University of Parma, Parma University Hospital, 14 - 43126 Parma, Italy.
Coronary microvascular dysfunction (CMD) comprises a wide spectrum of structural and/or functional abnormalities of coronary microcirculation that can lead to myocardial ischemia. Emerging evidence has indicated that CMD is a relevant cause of morbidity and mortality and is associated with a high risk of major adverse cardiovascular events (MACEs) and heart failure with preserved ejection fraction as well as poor quality of life. This review aims to elucidate briefly the pathogenesis and diagnostic modalities of CMD and to shed light on contemporary evidence on the prognostic impact of CMD.
View Article and Find Full Text PDFSafety and Efficacy of Baricitinib, Upadacitinib, and Sarilumab Implementation in Moderately-to-Severely Active Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Current Evidence.
Cureus
December 2024
Department of Anesthesiology and Intensive Care, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, GRC.
This study aims to assess the efficacy and safety of newly approved Janus kinase (JAK) and interleukin-6 (IL-6) inhibitors in patients with moderately-to-severely active rheumatoid arthritis (RA) with inadequate response to or intolerance of conventional disease-modifying antirheumatic drugs. We conducted a systematic review and meta-analysis of all placebo-controlled randomized trials assessing baricitinib, sarilumab, and upadacitinib treatment in RA, published in PubMed and CENTRAL (Cochrane Central Register of Controlled Trials) databases up to October 2023. The study outcomes involved the American College of Rheumatology (ACR) 20%, 50%, and 70% responses, Health Assessment Questionnaire-Disability Index (HAQ-DI), Disease Activity Score in 28 joints (DAS28), serious adverse events, and adverse events leading to drug discontinuation.
View Article and Find Full Text PDFRecent development of micro-nano carriers for oral antineoplastic drug delivery.
Mater Today Bio
February 2025
Department of Neurological Rehabilitation, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Chemotherapy is widely recognized as a highly efficacious modality for cancer treatment, involving the administration of chemotherapeutic agents to target and eradicate tumor cells. Currently, oral administration stands as the prevailing and widely utilized method of delivering chemotherapy drugs. However, the majority of anti-tumor medications exhibit limited solubility and permeability, and poor stability in harsh gastrointestinal environments, thereby impeding their therapeutic efficacy for chemotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!